Merrimack Pharmaceuticals Inc., a Cambridge company focused on developing cancer therapies, fell after it reported results from a mid-stage study involving the drug MM-121 in combination with Paclitaxel to treat platinum-resistant or refractory-advanced ovarian cancer. MM-121, being developed with Sanofi, did not meet its primary “endpoint” of improving progression-free survival. There was no statistical difference between MM-121 with Paclitaxel and Paclitaxel alone. Side effects like diarrhea and vomiting were more prevalent in the group taking MM-121. Full story for BostonGlobe.com subscribers.
This is a summary. To read the whole story subscribe to BostonGlobe.com
© Copyright 2013 Globe Newspaper Company.
Get the full story with unlimited access to BostonGlobe.com. Just 99¢ for 4 weeks.